Abstract
Everolimus (EVE) is a drug widely used in several renal transplant protocols. Although characterized by a relatively low nephrotoxicity, it may induce several adverse effects including severe fibro-interstitial pneumonitis. The exact molecular/biological mechanism associated to these pro-fibrotic effects is unknown, but epithelial to mesenchymal transition (EMT) may have a central role. Additionally, heparanase, an enzyme recently associated with the progression of chronic allograft nephropathy, could contribute to activate this machinery in renal cells.
Lingua originale | English |
---|---|
pagine (da-a) | 292-292 |
Numero di pagine | 1 |
Rivista | Journal of Translational Medicine |
Volume | 11 |
DOI | |
Stato di pubblicazione | Pubblicato - 2013 |
Keywords
- everolimus
- renal tubular cell